King of Prussia, Pennsylvania | December 23, 2025 — Phio Pharmaceuticals Corp. announced a significant advancement in its drug development program with the U.S. Food and Drug Administration accepting the nonclinical toxicology study design for its lead candidate PH-762. The study is scheduled to begin in Q1 2026, marking a critical step toward a pivotal human clinical trial and reinforcing the company’s regulatory trajectory for its INTASYL® siRNA gene-silencing platform in oncology.
Science Significance
The advancement of PH-762, an INTASYL® siRNA therapeutic targeting PD-1 gene expression, underscores meaningful scientific progress in non-surgical immuno-oncology approaches. PH-762 is designed for intratumoral delivery, enabling direct modulation of immune checkpoints within the tumor microenvironment. Recent Phase 1b dose-escalation data demonstrated encouraging safety and efficacy, with complete, near-complete, and partial pathological responses observed across multiple cohorts of patients with cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. Importantly, no dose-limiting toxicities or clinically relevant adverse events were reported, strengthening confidence in the compound’s biological mechanism and translational potential.
Regulatory Significance
From a cGxP and regulatory compliance perspective, FDA acceptance of the nonclinical toxicology protocol is a major regulatory milestone. This step reflects alignment with Good Laboratory Practice (GLP) requirements and is a prerequisite for advancing into pivotal clinical trials under Good Clinical Practice (GCP). Concurrently, Phio’s efforts to ensure commercially viable drug product manufacturing compliant with current Good Manufacturing Practices (cGMP) demonstrate an integrated development strategy that regulators increasingly expect. Collectively, these actions position PH-762 on a credible pathway toward future NDA submission, subject to successful clinical outcomes.
Business Significance
Advertisement
Strategically, the program milestone signals execution strength and disciplined capital deployment. Phio is allocating proceeds from its recent financing toward toxicology studies and cGMP manufacturing readiness, reflecting a focus on value-inflection points that matter to investors and partners. Positive interim clinical data combined with regulatory momentum enhances the commercial attractiveness of PH-762, potentially strengthening Phio’s position for future collaborations, licensing discussions, or strategic partnerships within the competitive immuno-oncology landscape.
Patients’ Significance
For patients, especially those with skin cancers requiring invasive surgical interventions, PH-762 represents a promising non-surgical therapeutic option. The absence of disease progression across treated patients and the high rate of pathological response highlight the potential for improved outcomes with reduced treatment burden. If further validated, this approach could offer localized, immune-enhancing therapy with favorable tolerability, addressing an unmet need among patients who are not ideal surgical candidates or who require alternative treatment strategies.
Policy Significance
At a policy level, the development of RNA interference–based immunotherapies like PH-762 aligns with broader healthcare priorities emphasizing precision medicine, innovation in oncology, and accelerated translational research. The program reflects how regulatory science and sponsor–FDA communication can streamline development while maintaining rigorous safety standards. Such progress supports policy frameworks that encourage advanced therapeutics, domestic manufacturing compliance, and early regulatory engagement to bring innovative treatments to patients efficiently.
With FDA-aligned nonclinical studies set to begin and cGMP manufacturing initiatives progressing, Phio Pharmaceuticals has strengthened the foundation for advancing PH-762 toward late-stage development. The convergence of robust early clinical data, regulatory alignment, and manufacturing preparedness positions the program as a noteworthy example of science-driven, compliance-focused biopharmaceutical development—making this milestone highly relevant for stakeholders across the cGxP ecosystem.
Source: Phio Pharmaceuticals Corp press release
